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Summary 
To gain insight into the rules that govern the binding of endogenous and viral peptides to a 
given major histocompatibility complex (MHC) class I molecule, we characterized  the amino 
acid sequences of a set of self peptides bound by a soluble analogue of murine H-2L  a, H-2Ld~. 
We tested corresponding synthetic peptides quantitatively for binding in several different assays, 
and built three-dimensional computer models of eight peptide/H-2Lds complexes, based on the 
crystallographic structure of the human HLA-B27/peptide complex. Comparison of primary 
and tertiary structures of bound self and antigenic peptides revealed that residues 2 and 9 were 
not only restricted in sequence and tolerant of conservative substitutions, but were spatially 
constrained in the three-dimensional models. The degree of sequence variability of specific residues 
in MHC-restricted peptides reflected the lack of structural constraint on those amino acids. Thus, 
amino acid residues  that define a peptide motif represent side chains required or preferred for 
a close fit with the MHC class I heavy chain. 
T 
he cell surface antigens encoded by the MHC class I genes 
consist of a polymorphic H  chain of 45 kD bound to 
a peptide of 8-10 residues and a noncovalently bound 12-kD 
L chain, 3z microglobulin (~2-m) 1 (1, 2). The bound pep- 
tides usually derive from the MHC-expressing cell and rep- 
resent proteolytic fragments of cytosolic, plasma membrane- 
associated, or secreted proteins (3, 4). Upon infection with 
cellular parasites such as viruses or bacteria,  specific peptide 
fragments can be bound by the class I molecule and displayed 
at the cell surface (5-7).  There, the MHC class I/peptide/ 
B2-m complex serves as a major element in the recognition 
of such infected cells by clonotypic TCRs (1, 8, 9). Detailed 
x-ray  structures of the MHC  class I  molecules HLA-A2 
(10-12),  HLA-A68 (13), HLA-B27 (14), and H-2K  b (15, 16) 
have been reported which reveal the intimate association  of 
self peptide with a groove supported by antiparallel/S-sheet 
and bounded by the helices of the oq and o~z domains. 
Several approaches have been employed to evaluate the na- 
ture of self and antigenic peptides bound to MHC proteins. 
First, the elution of peptides with acid,  the isolation of a 
single pool of peptides by reverse phase HPLC, and the de- 
termination of the preferred amino acids at particular posi- 
tions by automated Edman degradation, have led to the defini- 
tion of particular motifs for peptides bound to certain MHC 
molecules (2, 6,  17). Second, individual peptides have been 
identified by the sequencing of single HPLC fractions, using 
either classical techniques or mass spectrometry (3-5). In one 
case, the identification of the peptide sequence motifs was 
the basis of the molecular interpretation of electron density 
maps of the HLA-B27 molecule (14). Detailed evaluation of 
the ability of self peptides to bind the MHC H chain/B2-m 
complex from which they were eluted and the correlation 
of this binding with structural models has been limited (4, 
18). We report here the identification of self peptides eluted 
from a soluble analogue of H-2L  d, the evaluation of their 
binding to both the soluble H-2L  d as well as cell surface 
H-2L  d,  and  molecular  modeling of  the  similarities  and 
differences of eight H-2Ld/peptide/32-m  complexes. 
I Abbreviations  used in this  paper:/32-m,/32 microglobulin;  LCMV, lympho- 
cytic choriomeningitis virus;  MCMV,  murine cytomegalovirus; NHS, 
N-hydroxysuccinimide; ILU, resonance  unit. 
Materials and Methods 
Protein and Synthetic Peptides.  The soluble analogue of H-2L  ~, 
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of H-2L  d with the cr  domain and COOH terminus of Q10  b (19). 
Protein was immunoaffinity purified from transfectant L cell cul- 
ture supernatants on a 30-5-7S (20)-coupled Sepharose 4B column 
and concentrated by centrifugation (Centricon 10; Amicon Corp., 
Beverly, MA) (21). The mAb 30-5-7S is specific for the ~  do- 
main  of maturely  folded  H-2L  d molecules  (22-24).  Synthetic 
peptide corresponding to the H-2L  a restricted murine cytomega- 
lovirus (MCMV) pp89 early regulatory protein residues  168-176 
(YPHFMPTNL), pMCMV, was purchased from Synthecell Corp. 
(Kockville, MD) or provided by John Coligan of the Biological 
Resources Branch (BtLB), National Institute of Allergy and Infec- 
tious Diseases (NIAID). All other peptides (provided byJ. Coligan) 
were synthesized using standard Fmoc chemistry on peptide syn- 
thesizers, repurified by reverse phase HPI.C, and sequence confirmed 
on an automated sequenator.  A panel of synthetic peptides was 
patterned after the sequences identified for the acid-eluted  H-2L  a, 
self peptides with alanine residues inserted at positions where the 
sequence was not clearly defined. Each synthetic peptide was desig- 
nated by the HPLC fraction from which the sequence was origi- 
nally identified. A  peptide, pAPAL,  containing the H-2L  a core 
motif, APArL,  was also synthesized. 
PeFtide Ehtion and Sequence Analysis.  435 p.g of purified H-2Ld~ 
were brought to 0.1% TFA at ambient temperature and separated 
by reverse phase HPLC using a C18 column (Vydac, Hesperia, CA 
[4.6  x  250 mm, 5-#M particle size]). The sample was loaded in 
0.01% TFA in dHzO for 5 rain, and then eluted with a 0-60% 
linear acetonitrile gradient over 35 min as described (2). After the 
gradient, the remaining material was eluted with 10 min of 80% 
acetonitrile. The flow rate was 1 ml/min and the absorbance  was 
detected at 220 nm. 1-ml fractions were collected, dried by vacuum 
centrifugation, and recovered fractions 21-30 were sequenced  by 
automated Edman degradation on a sequenator (model 470A; Ap- 
plied Biosystems,  Inc., Foster City, CA), standardized  to a repeti- 
tive yield of 94%. Individual fractions were sequenced  so as not 
to overlook peptides that occurred at low abundance. Residues were 
identified by amino acid analysis on a model 120A PTH analyzer 
(Applied Biosystems,  Inc., Foster City, CA). All sequencing and 
amino acid analysis was performed by the BRB, NIAID (Frederick, 
MD).  Homologous sequences  were identified by searching the 
National  Biomedical  Research  Foundation  (NBRF)  data  bank 
using MacVector v.3.5  (International Biotechnologies Inc., New 
Haven, CT). 
Competitive Binding Analysis.  Synthetic pMCMV was radiola- 
beled at its NH2-terminal tyrosine residue  with t25I and purified 
by BioGel (Bio-Rad Laboratories,  Richmond, CA) P-2 gel filtra- 
tion and reverse phase  HPLC as described (21). Specific activity 
of the labeled peptide was 8.9  ￿  1015 dpm/mole for the experi- 
ments shown in Fig.  2, A  and B, and 9.6  ￿  l0 is dpm/mole in 
Fig. 2 C. Affinity-purified H-2Las (800 nM) was added to a mix- 
ture of 2 #M radiolabeled  peptide and varying amounts of cold 
competing peptides in 0.02% BSA in PBS. Samples were placed 
in siliconized, blocked (with 2% BSA [Grade V; Sigma Chemical 
Ce., St. Louis, MO] in 0.02% azide) and rinsed microfuge tubes, 
overlayed with light mineral oil, and incubated at 37~  for 45- 
47 h. Analysis of equilibrium binding was done by spin-column 
chromatography as described (21). For competition binding anal- 
ysis, bound and free counts for experimental and nonspecific con- 
trol samples were analyzed with LIGAND (Mac version 4.1) (25) 
and ALLFIT (Mac version  1.0) (26). 
Serological Detection  Using Surface Plasmon Resonance.  The 
binding of mAb 30-5-7S to various H-2La,/peptide  complexes was 
assessed by surface plasmon resonance using BI_A_core  TM (Pharmacia 
Biosensor, Piscataway, NJ). Ester groups of the carboxymethylated 
dextran matrix of the gold surface sensor chip CM5  TM (Pharmacia 
Biosensor AB, Uppsala,  Sweden) were chemically activated during 
a 6-min continuous flow (5 #l/min) exposure to 50 mM N-hydroxy- 
succinimide  (NHS) and 200 mM N-ethyl-N'-(3-dimethylamino- 
proD'l  ) carbodiimide hydrochloride (EDC),  and then covalently 
linked to the free amines of 30-5-7S (0.02 mg/ml in 10 mM Na 
acetate pH 5.0) for 6 rain. The remaining reactive  groups were 
then blocked with 1 M ethanolamine hydrochloride, pH 8.5. The 
integrated microfluidic cartridge (IFC) was thermally regulated at 
a constant temperature of 25~  and the photodiode array detec- 
tion signals were normalized with 40% wt/wt glycerol. Atl solu- 
tions were filtered and degassed. 50/zl of 10 #g/ml immunoaffinity 
purified H-2La~ (in 10 mM Hepes, pH 7.4,  150 mM NaCI,  3.4 
mM EDTA,  and 0.05% BIAcore Surfactant P20 (Pharmacia  Bi- 
osensor) (Hepes buffered saline  [HBS]) were added  to 50/zl of 
varying amounts of peptide in HBS or HBS alone at room temper- 
ature to achieve equilibrium (at least  15 h). 30-/xl aliquots were 
analyzed for direct binding to the immobilized 30-5-7S on the 
matrix surface by surface plasmon resonance (27-31). The flow rate 
was constant at 5 #l/min and the antibody surface was regenerated 
with a 1-min wash of 5 mM phosphoric acid. 1,000 resonance units 
(ILU) correspond to a surface concentration of •1  ng/mm  2. Nor- 
malized RUs  provided a quantitative indication of the mass of 
H-2Ld~ associated  with the antibody at a given time. 
Analysis of Sequence Variability.  Peptide sequences were analyzed 
for sequence variability according m the algorithm of Wu and Kabat 
(32), and for structural variability  according to Padlan (33) using 
the amino acid dissimilarity  values of Grantham (34). 
Molecular Modeling.  Three-dimensional coordinates for the HLA- 
B27/peptide complex were kindly provided by D. Madden and D. 
Wiley (Harvard University, Cambridge, MA) (14). The amino acid 
structures  corresponding to the H-2L  d sequence for residues 1-182 
(35-38), the Q10  b sequence for residues 183-275 (39), and for mu- 
rine fl2-m (40, 41) were substituted at the positions of the corre- 
sponding residues in the HLA-B27 structure using the computer 
graphics  program FRODO (42). Alpha carbons,  Ca, of the sub- 
stituted amino acids were superimposed  on the position of the C~ 
of the corresponding residue of HLA-B27. There was no need to 
introduce gaps in either sequence to maximize the homology align- 
ment. Similarly, antigenic peptide residues were substituted onto 
the corresponding positions of the HLA-B27 bound peptide. Pro- 
lines were substituted without difficulty in the trans configuration 
in all cases. After the substitution, the amino acid side chains were 
regularized to eliminate geometric incompatibilities, and the re- 
sulting coordinates were subjected to 40 steps of minimization using 
the Powell algorithm (43) in the program X-PLOR (44). These 
structures were subjected  to simulated  annealing (45,  46) using 
X-PLOR by heating to 1,000 ~ K and slow cooling to 300  ~ K. 
The only constraints in the simulated annealing were the disulfide 
bonds joining residues  101-164 and 203-259 of the H chain and 
residues  25-80  of the B2-m L  chain.  The structure was  again 
energy minimized through 120 steps of Powell minimization, and 
then  subjected  to minimization by the adopted basis  Newton- 
Raphson technique (47) through an additional 100 cycles. Final 
coordinates for each structure were compared for root mean square 
(rms) deviations and molecular surface exposure. Connolly (48) sur- 
faces were calculated  for a water probe of 1.7 ./l . Calculations 
were performed on VAX 8530 (Powell minimization and simulated 
annealing) and IRIS 4D/70G (Silicon Graphics Inc., Mountain View, 
CA) (ABNR minimization and graphics) (using QUANTA 3.2.3; 
Polygen Corp., Waltham, MA). The validity of the simulated  an- 
nealing procedure in building these models is emphasized by the 
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pared favorably with the crystal structure of HLA-A2 with rms 
deviation of all 275 C~ atoms of <  1.5/~. Atomic coordinates for 
the models described here will be made available on request. 
Results 
Our laboratory has demonstrated the biological function 
and binding of a viral antigenic peptide to a soluble analogue 
of the murine class I molecule H-2L  d, H-2Ld~ (21),  and we 
were interested in determining the sequence of self peptides 
that copurify with this molecule. H-2Ld~ was purified from 
transfected L cell culture supernatants by immunoadsorbent 
chromatography using a mAb (30-5-7S)  that recognizes a 
conformationally sensitive epitope found on mature, peptide- 
complexed H-2L  a molecules (49, 50) (Corr, M. and D. Mar- 
gulies, unpublished results).  Over 400/zg of purified H-2Ld~ 
were dissociated by treatment with acid, and the components 
of the class I ternary complex were separated by reverse phase 
HPLC  under  conditions  such  that  most  peptides  of 8-11 
residues in length would be eluted with retention times be- 
tween 20 and 29 min (2) (Fig. 1). Individual fractions (21-30), 
containing small pools ofpeptides, were subjected to sequence 
analysis using automated Edman degradation (Table 1). Fre- 
quently, the amino acid analysis of the first Edman step was 
heterogeneous,  so  assignments  at  the  first  position  were 
difficult. Fractions 21 and 22 failed to yield reliable sequence 
information,  Also,  the PTH amino acid yields for fractions 
250 k  , 
blank  ,j 
Figure 1.  Reverse  phase HPLC 
~I  J~*'  profile  of  H-2L  d,  molecules. 
~  : ~ ~  H-2La~ molecules were immuno- 
J  affinity purified, denatured with 
- -'-'-Y  0.1% TFA, and loaded onto a C18 
2so  .,  "  t~ i!  reverse  phase HPI.C column as de- 
I  H'2Lus  ;~ i i  scribed in Materials and Methods. 
~|  !~ t  ~  Peptides were then eluted with a  o(~  !r 
I!  ~-!~ "2~"";  ~  0-60% linear acetonitrile gradient  E 
between 5 and 40 rain. (Top)  mock 
~  ~  injection;  (bottom) H-2Ld,/pep  - 
j_v__  tide separation. Absorbance was 
0  10  20  3o  4o  measured at 220 nm and is plotted 
RETENTION TIME (mini  as millivolts. 
26 and 28 were too low in cycles seven and eight to conclude 
that these sequences terminated after step eight. 
The sequences obtained clearly indicate a peptide motif 
consisting of proline at position 2 and a COOH-terminal 
hydrophobic residue, predominantly leucine, phenylalanine, 
or methionine. In addition,  a preference for glutamine or 
asparagine at positions 3 and 8, and a predilection for a second 
proline were noted. In one case (fraction 24), a small amount 
of lysine was identified with the tenth degradative step. The 
H-2L  a motif has also been found in two previously described 
H-2L  a restricted peptides:  that  of the MCMV  pp89  im- 
mediate early regulatory protein, pMCMV (51), and that of 
Table  1.  Sequences of Elutecl Self Peptides 
Sequence 
Fraction  1  2  3  4  5  6  7  8  9  10  Homology 
21  no sequence 
22  no  sequence 
23  X  P  1  E  A  N  Y  Q 
24  A  P  Q  P  G  M  E  N 
25  q  P  Q  R  G  R  E  N 
26  X  P  q  P  G  R  E  Q 
27  X  P  Q  P  n  1  Y  Q 
28  X  P  a  X  a  y  p  Y 
29  Y  P  N  V  N  I  H  N 
30  X  P  Q  K  A  G  G  F 
Y  P  H  F  M  P  T  N 
Ik  P  Q  A  S  G  V  Y 
X  f  Mouse leukocyte common antigen  (6/8) 
F  k  Bovine endozepine  (5/10) 
F  S. erythraeus rKNA adenine N-6-methyltransferase (6/9) 
Mouse proline-rich protein  (6/7) 
1  Chicken class I  B chain  precursor (6/8) 
B. stearothermophihs superoxide dismutase (5/6) 
F  Mouse Duchenne muscular dystrophy (6/9) 
L  M  Mouse phosphoglycerate kinase (9/9) 
viral antigens 
L  pMCMV  pp89  168-176 
M  pLCMV  NP  118-126 
The material in recovered HPLC fractions 21-30 was sequenced by automated Edman degradation. The typeface classifications  for amino acids report- 
ed include: boldface for a unique residue; plain uppercase for a quantitatively dominant residue; and plain lowercase for a residue with the least assur- 
ance because of low quantity  or heterogeneity at that position.  Positions for which an assignment could not be confidently made are designated 
with an X. Homologous proteins were identified by searching the NBRF data bank. The homologous proteins are followed by the fraction of exact 
amino acid matches with identified residues in the sequenced fraction. Accession numbers for best matches were: fraction 23, MUSLCA26 (74); 
fraction 24, A32944 (75); fraction 25, XYSMRE  (76); fraction 26, A29149 (77); fraction 27, SOl172  (78); fraction 28, DSBSNF (79); fraction 
29, B27162 (80); and fraction 30, A25567 (81). 
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(Table 1). 
To identify possible sources for the copurified peptides, the 
NBRF  protein data base was  scanned for these sequences. 
The best protein matches and fractions of homology are in- 
dicted in Table 1. Only one completely homologous protein, 
namely phosphoglycerate  kinase,  a  cytosolic protein,  was 
identified. Homologous proteins for the identified sequences 
should have been readily found if these eluted peptides had 
originated  from  serum components. 
Binding of Synthetic Peptides to H-2Ld,.  To verify that the 
eluted peptides were capable of binding to H-2L  d. we used 
a set of synthetic analogues representing the sequenced pep- 
tides. When ambiguity at particular sequencing steps did not 
permit a firm assignment, alanine was substituted in the syn- 
thetic peptide to preserve chirality and to impose minimal 
bias upon the propensity to bind. One of the synthetic pep- 
tides, p29 (named for the eluted fraction number),  had an 
identical HPLC retention time as the eluted, sequenced pep- 
tide.  Others  differed, suggesting  that  the alanine  substitu- 
tions were not the original residues,  or that in some cases 
the length of the predominant species differed from the ap- 
parent  consensus  sequence tength. 
The synthetic peptides were analyzed for their ability to 
bind  to purified H-2Ld~ in cold competition with  radiola- 
beled pMCMV (Fig. 2, A-C). Four of the synthetic peptide 
analogues, three nonamers and one decamer (p25A, p27, p29, 
and p30; Fig. 2 A), competed better than cold pMCMV in 
solution binding  to H-2Las,  and two of the decamer pep- 
tides (p23 and p24A; Fig. 2, A  and B) did not compete. One 
of the two decamer peptides that did not compete (p24A) 
was resynthesized as a nonamer truncation, p24B, which com- 
peted effectively (Fig. 2 B). Thus the failure ofpeptide p24A 
to bind was due to the lysine residue at its COOH  terminus. 
An H-2L  a core motif peptide, APAAAAAAL  (abbreviated 
pAPAL) competed for binding within  an order of magni- 
tude of concentration of pMCMV. 
A  second  and  independent  assay  of peptide  binding  to 
soluble H-2Lds was employed, measuring the ability of the 
synthetic peptide to induce the formation of the conforma- 
tional epitope bound by the mAb 30-5-7S (49), using real 
time surface plasmon resonance (see Materials and Methods) 
(Fig.  2,  D-F)  (27-31).  Normalized RUs  provided a quan- 
titative indication of the mass of H-2Lds associated with the 
antibody at a given time.  The data in Fig.  2 D  show that 
p27, p29, and p30 were slightly more effective in inducing 
the formation of the 30-5-7S epitope than pMCMV, whereas 
another longer H-2L  d restricted peptide,  ptum  91A-  (53), 
minimally induced the epitope above the basal level. In Fig. 
2  E,  we  observe that  p24B  and  p25B  were  equivalent  to 
pMCMV,  whereas  p24A  (the decamer with  the  COOH- 
terminal lysine) was  substantially  worse (the half-maximal 
Table  2.  Calculated  Contacts and Surface Area of MHC-bound Peptides 
Atomic contacts 
Surface 
Buried  Exposed 
Peptide  Sequence  van der Waals*  H  bonds*  Ion pairs~  (Az)  II  (A2)  II 
Relative binding 
Competition  ~  Epitope induction** 
p25A  QPQRGRENF  158  18  2  587  418  +  +  +  + 
p27  APQPNLYQL  132  10  1  498  445  +  +  + +  (3.9)  +  + 
p29  YPNYNIHNF  199  10  1  589  438  +  + +  (1.8)  +  + 
pMCMV  YPHFMPTNL  196  15  1  608  375  +  +  (1.0)  +  + 
p24B  APQPGMENF  120  10  1  524  372  +  (0.4)  +  + 
pLCMV  RPQASGVYM  145  15  2  590  324  ND  + 
p25B  APQRGRENF  125  13  1  535  403  ND  +  + 
p30  APQKAGGFLM  138  14  1  572  387  +  +  +  +  + + 
pHLAB27  ARYAASTEL  125  13  1  556  371  ND  ND 
* Two atoms are said to be in van der Waals contact if they are within  the sum of their van der Waals' radii  +  0.5 A  of each other. 
* Two atoms are said to be hydrogen-bonded if they are within 2.9  + 0.5 A  of each other. 
S Two oppositely charged atoms are said to form an ion pair if they are within  2.85 -+ 0.5 A  of each other. 
Ir Molecular surface available to a spherical probe of 1.7 A radius was calculated for the indicated peptide/MHC  models and free peptides using the 
Connolly algorithm (82) in QUANTA 3.2. The exposed surface area of peptide in the complex is listed. The difference  between this area and total 
surface area of the free peptide is tabulated as buried surface area. 
￿82  Relative binding was assessed by competition for solution binding of radiolabeled pMCMV for H-2Lds using spin columns as described in Fig. 
2. For those peptides for which competition was assessed over a range of three orders of magnitude, the value of the Kd for a single site fit was 
compared with that of pMCMV as a reference and is given in parenthesis, p25A and p30 were assigned the semi-quantitative values based on graphic 
comparison of the other peptides. Binding was quantitatively compared using both ALLFIT (83) and LIGAND (25). For these competitive curves, 
the data were insufficient  for statistically significant discrimination between one- and two-site binding models. Binding is listed relative to the compe- 
tition with pMCMV:  +, 0.1-0.5-fold the binding with pMCMV;  + +, 0.6-1.5;  + + +,  1.6-2.0;  and  + + + +, >2.1-fold pMCMV binding. 
*'Relative binding was assessed by induction of the 30-5-7S epitope as described in Fig. 2. Half-maximal values for epitope induction are listed 
as:  +, <50%  the binding in the pMCMV; or  + +, >50%  the binding with pMCMV. 
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Figure 2.  Synthetic analogues of eluted self peptides bind to H-2L  d, 
molecules. Synthetic peptides as indicated were used to compete for binding 
of lzSI-labeled pMCMV to H-2Lds in solution (A-C), as described in 
Materials and Methods. The results of three separate experiments are shown 
in A-C, respectively, pMCMV (A), as a cold competitor, was the stan- 
dard in each of the three experiments. Names and sequences of other pep- 
tides are indicated. Each data point represents the mean of triplicate deter- 
minations.  Peptides  were  also  used  to  induce  the  c~2  domain 
conformationally sensitive 30-5-7S epitope on H-2L  d, molecules as mea- 
sured by real time surface plasmon resonance (D-F; see Materials and 
Methods).  Varying concentrations  of peptide were added in solution to 
purified H-2L  d, molecules. Normalized RUs represent the difference in 
RUs in the presence and absence of added peptide. 
concentration of peptide required for epitope induction is about 
three orders of magnitude higher), pLCMV and p25A ex- 
hibited a peculiar behavior in that they induced the forma- 
tion of the 30-5-7S epitope at low concentrations, but satu- 
rated at a lower plateau (Fig. 2, E and F). As shown in Fig. 
2 F, pAPAL was detectably and p23 substantially less effec- 
tive in inducing the epitope than pMCMV. 
To evaluate the binding behavior of these synthetic pep- 
tides in a functionally relevant manner, and to confirm that 
peptides eluted from a soluble analogue of H-2L  d could bind 
cell surface H-2L  d, we used them to inhibit the presentation 
of the pMCMV peptide by an H-2Ld-expressing L cell trans- 
fectant, T1.1.1,  to a pMCMV-specific,  H-2La-restricted T 
cell hybridoma, E1B6 (21). Four of the six synthetic peptides 
tested (p25A, p27, p29, and p30) inhibited the presentation 
of pMCMV to the hybridoma, whereas two peptides (p23 
and p24A), which had failed to bind in either the physical 
or the serological assays, were also unable to compete func- 
tionally (data not shown). 
Sequence and Structural Variability of H-2L~ Binding Pep- 
tides.  With the demonstration of the binding of several viral 
and self peptides, it is valuable to analyze the location and 
degree of variability  of their amino acids. Variability based 
on seven nonamer peptides shown to bind was calculated based 
on two algorithms: sequence variability  was computed ac- 
cording to Wu and Kabat (32), and structural variability was 
computed according to Padlan (33) (Fig. 3). Wu-Kabat vari- 
ability provides an indication of how many different amino 
acids are observed at a given position relative to the frequency 
of the most common amino acid at that position. This cal- 
culation treats both conservative  and radical  substitutions 
equivalently.  Structural variability as calculated according to 
Padlan imposes a bias dependent on the degree of chemical 
dissimilarity of the observed substitutions. Peptide amino acids 
at position 2 showed no variability  by either measure,  and 
positions 3, 8, and 9 had limited variability. In contrast, the 
remaining positions exhibited substantial variability, with po- 
sitions 1, 4, and 6 significantly greater by both algorithms. 
Molecular Modeling of the Peptide/MHC Complex.  In the 
absence of a high resolution x-ray crystallographic structure 
for H-2L  d, we have built molecular models of the H-2Ld,/ 
32-m/peptide complex. Madden et al.  (14) have published 
the x-ray  structure of the human class I  MHC  molecule 
HLA-B27 complexed to human 32-m, and have modeled the 
electron density in the binding cleft to a nonamer peptide, 
ARYAASTEL.  Since  the  overall  sequence  homology of 
H-2L  d, to HLA-B27 over the 275 residues of the crystallized 
H  chain is 76%  with conservation of features  such as the 
location of cysteine residues involved in intrachain disulfide 
bonds, it is reasonable to employ a mixture of heuristic and 
objective methods to develop such a model (54-57). Begin- 
ning with the coordinates derived from 3.0 A  resolution 
x-ray diffraction data of the HLA-B27/h32-m/peptide com- 
plex, provided by D.  Madden and D.  Wiley, the H-2Ld,/ 
mB2-m/peptide models were built by substituting the poly- 
morphic amino acid residues  of H-2L  a.  m132-m, and each 
of a set of H-2L  d restricted peptides, followed by regulari- 
zation, energy minimization, and simulated annealing (see 
Materials  and Methods). Independently derived models of 
the H-2Ld,/mB2-m/peptide complexes were  analyzed  for 
atomic contacts between the peptide and the H  chain, and 
for buried and exposed surface area of the peptides (see Table 
2). The number and kind of such contacts and the area of 
buried or exposed surface did not dearly correlate with the 
relative binding of the peptides to the class I molecule. 
The seven nonamer peptides shown to bind to H-2L  d, 
were also analyzed for the contributions of each residue to 
deviation from average position, average fractional accessi- 
bility to solvent, and total number of atomic contacts, and 
these were compared with the sequence and structural varia- 
bilities calculated above (see Table 3). In general, variability 
paralleled the rms deviation from the average position, with 
the exception of position 1, where variability was permitted, 
20+L  o+010oi 
~5c  15 
~g  to 
5 
0 
~'~  6o  ++ 
~  ~  40 
20 
0 
1  2  34  5  6  78  9 
Position 
Figure 3.  Sequence and struc- 
tural variability of seven H-2L  a- 
binding nonamer peptides.  Se- 
quences of peptides p25A,  p27, 
p29, pMCMV, p24B, pLCMV, and 
p25B were compared according to 
the methods  of Wu and Kabat 
(32) (.4) and Padlan (33) (B). 
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rms deviation  Average fractional 
Sequence  Structural  from average  accessibility  Total no. 
Position  variability*  variability~  position (A)s  ( + SD)II  atomic contacts  I 
1  9.3  64.6  0.61  0.09  -+  0.10  275 
2  1.0  0.0  0.79  0.00  _+  0.00  109 
3  4.2  13.0  0.91  0.24  +  0.12  128 
4  17.5  75.9  0.93  0.91  +  0.10  40 
5  9.3  47.2  0.85  0.67  +_  0.15  46 
6  21.0  87.3  1.06  0.90  _+ 0.09  53 
7  11.7  54.9  1.06  0.45  _+ 0.16  115 
8  4.2  27.8  0.67  0.74  _+ 0.06  37 
9  5.3  10.7  0.62  0.07  _+ 0.03  272 
Molecular models of each of the seven nonamer peptides, p25A, p27, p29, pMCMV, p24B, pLCMV, and p25B, bound to H-2L d, and mB2-m were 
constructed as described in Materials and Methods.  Indicated parameters were  calculated as follows: 
* Sequence variability was computed  using the formula of Wu and Kabat  (32). 
Structural  variability quantifies the structural differences among the various amino acid residues occurring  at each position and was computed  ac- 
cording to Padhn (33) using the amino acid dissimilarity values of Grantham (34). 
S Deviation of C,~ position  from  the average was calculated. 
II The fractional  accessibility of each amino acid residue,  defined as the amount of surface area that is accessible to a solvent probe  in the three- 
dimensional structure divided by the surface are that would be exposed if the residue Of) were in an isolated GIy-X-Gly tripeptide  with the same 
backbone configuration as the corresponding  tripeptide  in the structure,  was computed  according  to Pa~an (84). 
￿82  Two atoms  are said to be in contact if they are within the sum of their van der Waals' radii  +  0.5A  of each other. 
but large deviation in position was not observed. Residues 
1, 2, and 9 have very little exposed surface area on average, 
and residues 3-8 are generally exposed. The number of atomic 
contacts, as expected, inversely correlated with the exposed 
surface area: the most contacts are with atoms from residues 
1,  2,  3,  7,  and 9. 
Illustrations  of the  computer  models  of two  peptide/ 
H-2Lds complexes, the pMCMV nonamer and the p30 de- 
camer, are shown in Fig. 4. In each of these panels,  the stick 
figure of peptide including its side chains is shown with a 
partial ol carbon tracing of the H-2Las molecule. In Fig.  4, 
A and C, the side chain of the invariant residue, tryptophan 
147, is shown for reference. In addition, the solvent-exposed 
surface, as calculated by the Connolly algorithm (48), of the 
peptide residues in the complex is shown. In the pMCMW 
H-2Lds model (Fig.  4, A  and B), the side chain of the first 
residue of the peptide (tyrosine) is partially accessible to sol- 
vent, and the side chains of residues 4, 5, 6, and 7 are largely 
accessible to solvent. The model of the p30 decamer, which 
has a potentially flexible glycine-glycine sequence at positions 
6 and 7, is also well accommodated in the binding cleft (Fig. 
4, C and D). For comparison, the peptides of the pMCMV 
and p30 complexes have been superimposed (Fig. 5) to illus- 
trate the similarity of the backbone trace despite the differ- 
ence in length of one amino acid. 
Discussion 
In this paper we report the isolation of self peptides from 
a  soluble analogue of the murine MHC  class I  molecule, 
H-2L  a. their sequence determination, and the rebinding of 
synthetic peptides corresponding to those sequences to both 
purified soluble and cell surface H-2L  d. These peptides in- 
cluded both nonamers and decamers, consistent with  the 
findings of others who purified MHC class I from detergent 
extracts of cells and analyzed the peptides eluted from such 
preparations (2,  4,  58).  Unlike viral peptides eluted from 
H-2K  b (5) no octamers were clearly identified. 
A number of laboratories have examined self and viral pep- 
tides for their length and primary sequence, but few have 
reevaluated the sequenced peptides for the ability to bind to 
the MHC molecule from which they were eluted. As the 
Figure 4.  Molecular graphics models of the pMCMWH-2Lds and p30/H-2L  a, complexes. Computer models of pMCMV (YPHFMFFNL) com- 
plexed to H-2L a, (,4 and B), and p30 (APQKAGGFLM) complexed to H-2Lal (C and D) were generated as described in Materials and Methods.  c~ 
carbon backbone structure of the cq and ota helices and the invariant tryptophan side chain 147 are indicated in the en face view (A and C). The 
side views (B and D) show the/3-sheet floor and only the ~1 domain for clarity. (Dots) Solvent-accessible surfaces of the bound peptides. 
Figure 5.  Structure  of the modeled pMCMV (nonamer) and p30 (decamer) ~ptides. Computer models were generated as described in Materials 
and Methods. The bound peptides of the modeled comple~es are superimposed in this display, pMCMV (yellow); p30 (red). The NH2 termini (tyrosine 
for pMCMV,  and alanine for p30) are to the left,  and the COOH termini are to the right. 
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of sequential  Edman degradative steps may appear  to indi- 
cate termination prematurely, a second step to verify that these 
peptide sequences represent bound peptides was necessary. 
We have demonstrated binding of synthetic analogues of the 
H-2Ld,-eluted peptides using several independent assays: so- 
lution binding by competition, epitope induction using sur- 
face plasmon resonance to evaluate the presence of the c~2 
domain 30-5-7S conformationally sensitive epitope, and com- 
petition for presentation by  an  H-2Ld-expressing L  cell. 
Overall, these peptides bound at apparent affinities comparable 
with those of the reference peptide, pMCMV. 
Binding in solution permitted quantitative comparison of 
the binding of the test peptides as compared with the refer- 
ence tzSI-labeled peptide, pMCMV. Several peptides bound 
better than pMCMV: p25A, p27, p29, and p30. Competi- 
tion by the decamer peptide p30 supported the view that longer 
peptides may bind. However, the inability of the other two 
decamer peptides, p23 and p24A, to compete with pMCMV 
for binding illustrated the potential difficulties in identifying 
peptides by protein sequencing of HPLC fractions of acid- 
eluted material. The decamer p24A, with a questionable as- 
signment of lysine at the COOH terminus, did not bind; 
however, the nonamer p24B terminating with phenylalanine 
did. The identification of the permissive COOH terminus 
of this peptide supported the dominant motif for H-2L  d 
binding, namely a proline at position 2 and a leucine, phenylala- 
nine, or methionine at position 9 or 10. In addition, the motif 
peptide, pAPAL, bound well in the solution assay, although 
about an order of magnitude worse than pMCMV. 
The results of the solution binding assay were qualitatively 
consistent with those of the epitope induction assay detecting 
the conformational c~2 domain epitope, 30-5-7S. In the so- 
lution binding assay (Fig.  2, A-C) p23 and p24A did not 
compete detectably for binding by pMCMV, but in the epi- 
tope induction assay (Fig. 2, D-F), both peptides (at about 
100- and 1,000-fold the pMCMV concentration) could in- 
duce the epitope. Whether the induction of epitope directly 
and quantitatively correlates with peptide binding is not yet 
established,  and the apparent quantitative discrepancies be- 
tween the solution binding assay and the epitope induction 
assay may indicate that the two are not firmly linked. 
The motif was also confirmed by the demonstration that 
a motif peptide, pAPAL (APAAAAAAL), could effectively 
bind both in the solution binding and epitope induction assays. 
This finding is consistent with that of Maryanski et al. (59) 
who  demonstrated in  functional competition assays that 
H-2K  d could bind the consensus peptide AYPPPPPTLA or 
AYGGGGGGTLA, and that of Jardetzky et al.  (60) who 
demonstrated the binding of a similar substituted motif  pep- 
tide (AAYAAAAAAKAAA) to the class II MHC molecule, 
HLA-DR1. 
To examine the implied structural constraints of the eluted 
self peptides, we built eight independent computer models 
of the H-2LaJm~2-m/peptide complex. Our models, which 
take advantage of the similarity of the primary structures of 
the mouse H-2L  d, and human HLA-B27 MHC class I mol- 
ecules, and the HLA-B27 structure, depict the bound pep- 
tides  in  extended  conformations.  These  models  contrast 
markedly with one recently presented by Rognan et al. (61) 
in which the pMCMWH-2L  d complex was modeled from 
first principles.  In that model, the peptide was built as an 
c~-helix without benefit of the crystallographic data of MHC 
bound peptides.  Although considerable evidence implicates 
the propensity for a helical or amphipathic helical structure 
as a predictor of MHC-restricted antigenic peptides (62-65), 
the analysis of functional MHC-restricted peptide binding 
(59, 66, 67), of the solution structure of antigenic peptides 
thought to be helical by predictive algorithms (68),  and of 
the three-dimensional structure of peptides bound to HLA 
class I molecules (12, 14), and more recently H-2K  b (15), in- 
dicates that the peptide is probably in an extended confor- 
mation. 
The apparent requirement for proline at position 2 raises 
the possibility of at least two contributing factors:  (a) the 
specific geometry, particularly with respect  to peptide res- 
idue 1, contributed by the proline in either a c/s or trans  configu- 
ration; and (b) the spatial conformation and charge of the 
region of H-2L  a that putatively interacts with the side chain 
of position 2. Our molecular model of pMCMWH-2Lds in- 
dicates  that  the  NH2-terminal  amine  of  the  peptide  is 
hydrogen bonded to the hydroxyl oxygen of tyrosines 7, 59, 
and 171. The geometry of proline at 2 constrains the posi- 
tion of the tyrosine at position 1 to allow these bonds. The 
N-C,,-C dihedral angle of the arginine at peptide position 
2 of HLA-B27 has a similarly restrained orientation as the 
trans proline in our models of the H-2Ld~-bound peptides. 
It is interesting that the energy stabilization  contributed by 
the hydrogen bonding of the NH2-terminal amine is con- 
sistent with the findings of Fersht et al.  (69) who found a 
difference of ~3 kcal mol-1 for the energy contributed by 
a hydrogen bond to a charged, as compared to an uncharged 
donor or  acceptor.  Thus,  a hydrogen bond to  a charged 
NH2-terminal amine is about 3 kcal mol-1 stronger than 
one to an uncharged amine such as one in a peptide bond. 
The sequence restrictions at positions 2 and 9 found in 
our  motif can  be  further  understood by  inspecting  the 
H-2Ldffpeptide models for the areas of H chain where these 
peptide residues interact, namely the B and F pockets. In the 
H-2LaffpMCMV model, atoms of the H  chain that are in 
contact with the proline derive from tyrosine 7, arginine 62, 
isoleucine 63, isoleucine 66, tyrosine 99, tyrosine 159, and 
glutamic acid 163. In contrast with the B pocket of HLA- 
B27 which is lined by the following residues: tyrosine 7, histi- 
dine 9,  threonine 24,  valine 25,  valine 34,  glutamine acid 
45, glutamic acid 63, isoleucine 66, cysteine 67, lysine 70, 
and tyrosine 99, the corresponding region of H-2La~ differs 
with glutamic acid at 9, serine at 24, tyrosine at 45, isoleu- 
cine at 63, alanine at 67, and glutamine at 70. Thus, the B 
pocket of H-2L  d is partially closed off by the bulky tyrosine 
side chain at position 45. This may restrict the size of the 
side chain that can be easily accommodated by the pocket. 
In addition, the salt bridge linking the e~l to the ol2 helix, 
arginine 62 to glutamic acid 163, provides a canopy that con- 
strains  the proline at position 2.  It is likely that for some 
peptides, serine or alanine at position 2 is acceptable, since 
1688  H-2L  d Endogenous  Peptides: Motif, Binding,  and Molecular Modeling alanine  and serine have side chain volumes and hydropho- 
bicity very similar to proline (34, 70). Evidence that serine 
is permitted at position 2 includes the identification of a self 
peptide LSPFPFDL by  Udaka  et  al.  (71) that  sensitizes 
H-2La-expressing  cells  for  recognition by  an  allospecific 
CTL done. The tum 91A-  peptide, ISTQNHKALDLVA, 
described by Lurquin et al. (53),  and shown to induce the 
30-5-7S epitope on H-2L  a positive cell surfaces in the pres- 
ence of serum (24) has a serine in position 2, and most likely, 
the minimal core peptide is ISTQNHKAL (Corr, M., and 
D. Margnlies, unpublished data). In addition, a pMCMV ana- 
logue with alanine at position 2, although it has drastically 
decreased activity,  still binds detectably (72) (Boyd, L., M. 
Corr, S. Kozlowski, R. Kibaudo, and D. Margnlies, unpub- 
lished data). 
The identity of the COOH-terminal residue as leucine, 
phenylalanine, or methionine is consistent with the findings 
of Bordo and Argos (73) who demonstrated the constraints 
on allowed amino acid substitutions in proteins. They ob- 
served the likelihood of substitution of isoleucine,  leucine, 
valine, and methionine for one another, and noted the ability 
of phenylalanine to substitute for leucine in protein cores. 
Scrutiny of the region of H-2Las, which interacts with the 
COOH-terminal residue (the F pocket of Garrett et al. [13]) 
reveals that the hydrophobic side chain of the peptide pro- 
trudes into a pocket lined by tryptophan 73,  leucine 81, 
phenylalanine 116, tyrosine 123, threonine 143, and tryto- 
phan 147 (which hydrogen bonds to the carbonyl oxygen 
of the eighth residue of the peptide). Leucine fits well into 
this pocket, and the model of p29 with H-2Las indicates that 
the COOH-terminal phenylalanine of p29 can also stack with 
tryptophan 73, phenylalanine 116, and tryptophan 147. 
Computer graphic depiction of the peptide binding groove 
with the pMCMV peptide in place is shown in Fig.  4.  In 
these views,  the H-2La+ oe-carbon backbone and the side 
chain of the invariant tryptophan at position 147 (Fig. 4 A 
only) are shown. Solvent accessibility is depicted by the dot 
surface. The side chain of the NH2-terminal tyrosine residue 
at  position 1  is  accessible to  solvent, whereas  the NH2- 
terminal alanine of the decamer is not. The decamer model, 
in which the NH2 and COOH termini were first superim- 
posed on the first and ninth residues of the HLA-B27 bound 
peptide, and the intervening residues were then placed, re- 
veals similarity in the basic backbone trace, likely due to the 
flexibility of the glycine-glycine sequence at positions 6 and 
7 (Fig. 5). Thus, reasonable models for decamer peptide/class 
I complexes can be generated by fixing the appropriate pep- 
tide residues in the B and F pockets first. 
The comparison of the sequences and the structural models 
was carried out in two ways. First, we analyzed the peptides 
in toto and compared each model with the others (Table 2). 
No striking predictor of strength of binding was observed. 
When the individual peptides were compared with one an- 
other on a residue by residue basis, however (Table 3), it be- 
came clear that residues that permit sequence and structural 
variability  also have greater deviation from the mean posi- 
tion, greater fractional exposed surface area, and fewer atomic 
contacts. Conversely, residues with lower variability in general 
make more atomic contacts with the MHC molecule, are 
spatially more constrained, and are less exposed to solvent. 
While this manuscript was under review, the structures 
of two complexes of viral peptides with the mouse H-2K  b 
molecule were published (15, 16). These structures and those 
that we have modeled show remarkable similarity. In partic- 
ular, the backbones of the peptides are in an extended con- 
formation, and prolines are in trans. Longer peptides are ac- 
commodated because of their central flexibility. 
In conclusion, we have demonstrated that an immunoad- 
sorbent purified, soluble analogue of the murine MHC class 
I molecule, H-2Las, contains bound self peptides that can be 
eluted with acid, fractionated by HPLC, and sequenced. Syn- 
thetic peptides corresponding to these sequences can be tested 
for binding by any of several methods, and three-dimensional 
models of the peptide/MHC complexes can be made by sub- 
stitution of residues  onto the HLA-B27/peptide crystallo- 
graphic coordinates,  followed by simulated annealing and 
energy minimization. The resulting models permitted com- 
parison of sequence and structural variability  with solvent 
accessibility of the bound peptide and spatial deviation of 
specific amino acid residues. Such analysis permitted a unified 
view of the rules that govern MHC/peptide binding: specific 
interactions in pockets as proposed by Garret et al. (13), and 
variability  in the nonpocket regions. Such determination of 
constrained and variable portions of MHC-restricted anti- 
genic peptides, in addition to furthering our overall under- 
standing of the way these unique peptide receptors function, 
should permit the design of peptides for blocking or enhancing 
immune responses. 
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